SQI partners with McMaster to co-develop ’instant immunoassay’ testing technology

TORONTO, July 24, 2017 /PRNewswire/ – SQI Diagnostics (TSX-V: SQD; OTCQX: SQIDF), today announced a technology development partnership and licensing agreement with the McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing.

SQI is a Toronto-based life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced multiplexed diagnostics. SQI’s existing proprietary technology enables global pharmaceutical and diagnostic testing companies to perform highly complex multiplex tests much faster, more accurately and at a lower cost.

Source: SQI partners with McMaster to co-develop ’instant immunoassay’ testing technology

Share